{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:58:55Z","timestamp":1788184735982,"version":"build-2803163510"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:00:00Z","timestamp":1669334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100006407","name":"Natural Science Foundation of Henan Province","doi-asserted-by":"publisher","award":["2021JJ80083"],"award-info":[{"award-number":["2021JJ80083"]}],"id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Myasthenia gravis (MG) is a rare but life-threatening adverse event with pembrolizumab. What is known about pembrolizumab-induced MG is largely based on case reports. This analysis collected pembrolizumab-induced MG cases from Chinese and English databases published from September 1, 2014, to June 30, 2022. Demographic and clinical information of the patients, management, and outcome data were collected and analyzed. Sixty-five patients with a median age of 73 years (range 30\u201386), including 43 male patients (66.2%), were included. Eight patients (12.3%) with prior MG experienced worsening symptoms after receiving pembrolizumab. The median time to the onset of MG was four weeks (range 0.7\u201327). The most common symptoms were ptosis (81.5%, 53 patients), diplopia (50.8%, 33 patients), dyspnea (44.6%, 29 patients), trunk or peripheral weakness (43.1%, 28 patients), and dysphagia (30.8%, 20 patients). Concurrent myositis and myocarditis occurred in 13 (20.0%) and 17 patients (26.2%). Pembrolizumab was discontinued in 63 patients (96.9%). Forty-four patients (67.7%) received combination therapies based on steroids (intravenous immune globulin, plasmapheresis, or immunosuppressants). Twenty-seven patients (41.5%) had symptoms completely recovered. Fourteen patients (21.5%) died from immunotoxicity or primary cancers. Clinicians should consider the possibility of pembrolizumab-induced MG, especially during the first eight weeks of therapy. Patients should be treated as early as possible, regardless of the severity of the initial symptoms.<\/jats:p>","DOI":"10.1093\/cei\/uxac108","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T12:08:47Z","timestamp":1669378127000},"page":"85-92","source":"Crossref","is-referenced-by-count":13,"title":["Clinical features, diagnosis, and management of pembrolizumab-induced myasthenia gravis"],"prefix":"10.1093","volume":"211","author":[{"given":"Shaoli","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Endocrinology, The Third Xiangya Hospital, Central South University , Changsha, 410013 Hunan , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulu","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hunan Provincial Maternal and Child Health Care, Hospital Changsha , 410028 Hunan , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Third Xiangya Hospital, Central South University , Changsha, 410013 Hunan , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuojun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Third Xiangya Hospital, Central South University , Changsha, 410013 Hunan , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6067-8305","authenticated-orcid":false,"given":"Chunjiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Third Xiangya Hospital, Central South University , Changsha, 410013 Hunan , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,11,25]]},"reference":[{"key":"2023081113340371800_CIT0001","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1007\/s40265-014-0314-5","article-title":"Pembrolizumab: first global approval","volume":"74","author":"Poole","year":"2014","journal-title":"Drugs"},{"key":"2023081113340371800_CIT0002","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2023081113340371800_CIT0003","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejca.2021.01.048","article-title":"Immune-related adverse events after a single dose of pembrolizumab","volume":"148","author":"Vos","year":"2021","journal-title":"Eur J Cancer"},{"key":"2023081113340371800_CIT0004","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1517\/14740338.2015.1021774","article-title":"Safety of pembrolizumab for the treatment of melanoma","volume":"14","author":"Martin-Liberal","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"2023081113340371800_CIT0005","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1080\/21645515.2016.1199310","article-title":"Pembrolizumab (Keytruda)","volume":"12","author":"Kwok","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"2023081113340371800_CIT0006","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"key":"2023081113340371800_CIT0007","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","article-title":"Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors","volume":"82","author":"Makarious","year":"2017","journal-title":"Eur J Cancer"},{"key":"2023081113340371800_CIT0008","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.yfrne.2014.04.004","article-title":"Gender differences in autoimmune disease","volume":"35","author":"Ngo","year":"2014","journal-title":"Front Neuroendocrinol"},{"key":"2023081113340371800_CIT0009","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol"},{"key":"2023081113340371800_CIT0010","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","article-title":"Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan","volume":"89","author":"Suzuki","year":"2017","journal-title":"Neurology"},{"key":"2023081113340371800_CIT0011","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.lungcan.2019.06.015","article-title":"Fatal adverse events in two thymoma patients treated with anti-PD-1 immune check point inhibitor and literature review","volume":"135","author":"Konstantina","year":"2019","journal-title":"Lung Cancer"},{"key":"2023081113340371800_CIT0012","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1196\/annals.1254.043","article-title":"Susceptibility of ocular tissues to autoimmune diseases","volume":"998","author":"Kaminski","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"2023081113340371800_CIT0013","doi-asserted-by":"crossref","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of immunotherapy-related toxicities, version 1.2019","volume":"17","author":"Thompson","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"2023081113340371800_CIT0014","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000498985","article-title":"Cardiac toxicity associated with immune checkpoint inhibitors: case series and review of the literature","volume":"12","author":"Agrawal","year":"2019","journal-title":"Case Rep Oncol"},{"key":"2023081113340371800_CIT0015","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","journal-title":"J ImmunoTher Cancer"},{"key":"2023081113340371800_CIT0016","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"2023081113340371800_CIT0017","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.2169\/internalmedicine.8554-21","article-title":"Pembrolizumab-induced myasthenia gravis relapse after immunosuppressive therapy","volume":"61","author":"Oshima","year":"2022","journal-title":"Intern Med"},{"key":"2023081113340371800_CIT0018","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s11060-018-2752-5","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"137","author":"Fellner","year":"2018","journal-title":"J Neurooncol"},{"key":"2023081113340371800_CIT0019","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s13256-021-02722-8","article-title":"Pembrolizumab-induced myasthenia gravis-like disorder, ocular myositis, and hepatitis: a case report","volume":"15","author":"Tian","year":"2021","journal-title":"J Med Case Rep"},{"key":"2023081113340371800_CIT0020","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/CMR.0000000000000310","article-title":"Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients","volume":"27","author":"Nguyen","year":"2017","journal-title":"Melanoma Res"},{"key":"2023081113340371800_CIT0021","doi-asserted-by":"crossref","first-page":"100324","DOI":"10.1016\/j.ensci.2021.100324","article-title":"Detect it so you can treat it: A case series and proposed checklist to detect neurotoxicity in checkpoint therapy","volume":"22","author":"Bolz","year":"2021","journal-title":"eNeurologicalSci"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cei\/advance-article-pdf\/doi\/10.1093\/cei\/uxac108\/48803898\/uxac108.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/211\/2\/85\/51098438\/uxac108.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/211\/2\/85\/51098438\/uxac108.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T13:34:19Z","timestamp":1691760859000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/211\/2\/85\/6846468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,25]]},"references-count":21,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,11,25]]},"published-print":{"date-parts":[[2023,3,16]]}},"URL":"https:\/\/doi.org\/10.1093\/cei\/uxac108","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2,1]]},"published":{"date-parts":[[2022,11,25]]}}}